Page 120 - Drug Class Review
P. 120
Page 90 of 205
Drug Effectiveness Review Project
placebo 69.4 66 100 62%, 38% 16.6 26.90 ome Measures: ADAS-J-Cog; J-CGIC Significantly more improvement in CMCS for DON-treated patients (P = 0.01) at endpoint DON was significantly better than placebo on ADAS-J-Cog (P = 0.003) and J-CGIC (P < 0.001)* Significantly more improvement in CDR-SB for DON-treated patients (P < 0.001) at endpoint Significantly more improvement in MENFIS for DON-treated patients (P = 0.004) at endpoint
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes
donepezil 70.1 68 100 68%, 32% 17.8 22.91 Secondary Outcome Measures: CDR-SB; MENFIS; CMCS Timing of assessments: Baseline and every 4 weeks Health Outcome Measures: Intermediate Outcome Measures:
Primary Outc • • • •
Final Report Update 1 Authors: Homma et al. Year: 2000 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% Japanese): Other germane population qualities: CDR 1,2 • Mean baseline MMSE • Mean ADAS-J-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
